No Data
No Data
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
Cathie Wood's ARK Investment Buys 485K Shares of Beam Therapeutics Today
Beam Therapeutics Raised to Buy From Hold by Jones Trading
Beam Drops 9% on Phase 1/2 Data for Genetic Lung Disease Candidate
Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Beam Therapeutics Analyst Ratings
TheOracleOfBroMaha : WOW THE Days To Cover is/has been 6-10+ with a TON OF SHARES IN FLOAT! nice
Smokey The Bear OP TheOracleOfBroMaha : always nice!